We take a full-circle approach to product development, from the grassroots level to the lab to legislative bodies.


To translate scientific discoveries into affordable, globally accessible public health solutions.


A world where all people have equitable access to innovative vaccines and therapeutics.

Our health areas

  • HIV
  • Tuberculosis
  • Lassa fever
  • Marburg virus
  • Sudan Ebolavirus
  • COVID-19


The challenge

HIV/AIDS remains one of the deadliest infectious diseases, with 1.3 million people acquiring HIV in 2022. Given the complexities of HIV, traditional approaches to vaccine development have so far failed to result in a vaccine that provides protection against HIV. However, a vaccine is still needed to bring a true end to the HIV pandemic. Source: UNAIDS

Our solution

IAVI scientists and our collaborators are developing next-generation HIV vaccines to address the challenges of HIV vaccine design. Together, we have pioneered promising new vaccination strategies and the discovery of broadly neutralizing antibodies (bnAbs) against HIV. IAVI and our partners are developing HIV bnAbs to prevent HIV acquisition while we advance vaccine candidates.


The challenge

Tuberculosis (TB) is the world’s leading infectious disease killer. In 2022, 10.6 million people fell ill with TB and 1.3 million people died of TB disease. The only available TB vaccine is the century-old Bacille Calmette-Guérin, or BCG. While this vaccine has efficacy in protecting against severe TB disease in infants and young children, it is largely ineffective in adolescents and adults, among whom most transmission and disease occurs. Source: WHO

Our solution

IAVI works across our global hubs with a diverse network of partners to advance the most promising TB vaccine candidates from discovery through clinical trials, and eventually, to post-licensure access. Our work extends to policy and advocacy initiatives that support TB vaccine development and access in regions where new vaccines are needed most.

Lassa fever

The challenge

Lassa fever is an acute viral hemorrhagic illness endemic to West Africa that causes significant annual outbreaks of disease. Lassa fever is difficult to diagnose, and surveillance data is limited. Current estimates range from 300,000 to 500,000 cases and 5,000 related deaths each year. No licensed vaccines for Lassa fever exist. Source: WHO

Our solution

IAVI is developing a single-dose vaccine candidate for Lassa that is based on a recombinant vesicular stomatitis virus (rVSV) vector. This technology is similar to that underlying an approved Ebola Zaire virus vaccine. IAVI’s Lassa vaccine candidate was well tolerated and immunogenic over a wide dose range in a Phase I clinical study. IAVI also conducts Lassa epidemiological studies and modeling to support future vaccine access.

Marburg virus

The challenge

Marburg virus is a filovirus and the causative agent of Marburg virus disease (MVD), which has a case fatality ratio of up to 88%. Marburg virus has the capacity to cause outbreaks with high fatality rates and is a potential bioterror threat. No vaccines or antiviral treatments are approved for MVD. A Marburg vaccine is urgently needed to respond to future outbreaks. Source: WHO

Our solution

IAVI is developing a vaccine candidate for Marburg that is based on a recombinant vesicular stomatitis virus (rVSV) vector. This technology is similar to that underlying an approved Ebola Zaire virus vaccine, which is now approved by the U.S. FDA and registered for use in several African countries. Preclinical data demonstrates that IAVI’s Marburg vaccine candidate is highly protective in an animal model with one dose.

Sudan Ebolavirus

The challenge

Sudan ebolavirus is a filovirus and causes outbreaks of Ebola disease, most recently in 2022 in Uganda. Case fatality rates of Ebola disease caused by Sudan ebolavirus have varied from 41% to 100% in past outbreaks. The licensed vaccine for Ebola Zaire virus does not provide cross protection against the Sudan strain. An Ebola Sudan vaccine is urgently needed to prevent and respond to future outbreaks. Source: WHO

Our solution

IAVI is developing a vaccine candidate for Sudan ebolavirus that is based on a recombinant vesicular stomatitis virus (rVSV) vector similar to the technology underlying an approved Ebola Zaire virus vaccine. During the 2022 Ebola outbreak in Uganda, the WHO selected IAVI’s Sudan ebolavirus vaccine candidate for a planned ring vaccination trial. While the trial did not go forward due to outbreak control, IAVI has continued clinical development to prepare for future outbreaks.


The challenge

Since December 2019, over 760 million cases of COVID-19 and 6.9 million deaths have been recorded worldwide, but the actual number is thought to be higher. While highly effective, approved COVID-19 vaccines do not fully block transmission or breakthrough infection. Additional COVID-19 vaccines continue to be an urgent need, particularly vaccines suitable for widespread use in middle and low-income countries. Source: WHO

Our solution

IAVI is developing a COVID-19 vaccine candidate that is based on a recombinant vesicular stomatitis virus (rVSV) vector. The vaccine candidate has demonstrated safety in humans when administered intramuscularly and has been produced at scale to support larger future clinical trials. IAVI is also investigating an intranasal formulation of our COVID-19 vaccine candidate to prevent infection.

Our impact

We conduct preclinical and clinical trials of our own vaccines and antibodies. Our focus is on diseases of global importance for which there is no market and little financial incentive for development. We also collaborate with and support other scientific organizations to conduct their own clinical trials of priority disease prevention and therapeutic interventions.

255 partners from academic, biotech, pharma sectors, civil society, and global health initiatives

53 biologics candidates supported by the IAVI Product Development Center, out of which 25 advanced to clinical trials

70,000 volunteers enrolled in observational epidemiology studies

Our locations

IAVI Africa

  • Cape Town Office, South Africa
  • Nairobi Office, Kenya

IAVI Europe

  • Amsterdam Office, The Netherlands
  • Human Immunology Lab, London, U.K.

IAVI India

  • Gurugram, Haryana Office
  • Antibody Translational Research Program, IAVI-THSTI, Faridabad


  • New York Office
  • Vaccine Design & Development Lab, New York
  • Neutralizing Antibody Center, California

Recent news & media

Iavi C105 Lassa Vaccine Trial Nigeria
Press Release

Participants in Nigeria vaccinated in first-ever Phase 2 Lassa fever vaccine clinical trial, sponsored by IAVI

Key takeaways: Participants at HJF Medical Research International in Abuja, Nigeria, have been vaccinated in the first Phase 2 clinical trial of a Lassa fever virus (LASV) vaccine candidate to date, according to IAVI, a nonprofit scientific research organization and the trial sponsor. The study (IAVI C105/PREVAIL15) is funded by CEPI, an innovative global partnership […]
Read More
Iavi World Vaccine Congress 2024

World Vaccine Congress highlights IAVI’s R&D from end to end

IAVI’s leaders are excited to participate in the World Vaccine Congress 2024, taking place April 2-4 in Washington, D.C. The conference convenes over 4,000 attendees to hear from hundreds of speakers addressing some of the most exciting opportunities and challenges of vaccine development. The conference agenda covers the end-to-end development of vaccines, from discovery to […]
Read More
IAVI Report

Don’t Stop Believin’: This year’s HIV vaccine research theme

The titles of HIV vaccine sessions at scientific conferences tend to epitomize the current sentiments of the field. Over the years these session titles have on occasion conveyed optimism, while at other junctures communicated a more dire call for a “back to basics” approach. But most often, following a series of disappointing results from clinical […]
Read More
Syphilis bacteria illustration
IAVI Report

With syphilis, it’s yesterday once more

“I don’t know if my colleague Jonathan Volk is in the audience,” says the sexually transmitted infection expert, clinician, and writer, Ina Park. “But every time he gets a consultation, he just picks up the phone and says, ‘It’s syphilis.’” She is kidding, mostly. But these days the call would be right more often than […]
Read More
CELEBRATE study team outside the South African Medical Research Council after a site visit in December 2023.

IAVI and partners kick-start CELEBRATE study to explore acceptability and feasibility of bnAbs for infant HIV prevention 

IAVI, a non-profit organization dedicated to accelerating the development of vaccines and antibodies against infectious diseases, has announced the commencement of the CELEBRATE study, aimed at understanding the acceptability and feasibility of utilizing broadly neutralizing antibodies (bnAbs) for the prevention of HIV acquisition in infants. The study marks a significant step forward in the quest […]
Read More
Computer image of the eOD-GT8 immune-stimulating protein. Image courtesy of Joseph Jardine, Sergey Menis, and William Schief of Scripps Research and IAVI.

IAVI statement on mRNA HIV vaccine candidate trials

IAVI is currently in the process of finalizing and submitting a manuscript for publication of the results of the IAVI G002 clinical trial. The forthcoming publication will describe in detail both the immune responses and the safety outcomes observed in the trial.   On March 1, Science published a news article about skin events observed in […]
Read More